In the ECHELON-2 trial, which evaluated therapies for CD30-positive peripheral T-cell lymphoma (PTCL), brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) was compared with standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) in CD30-positive PTCL patients. Here, TNFRSF8 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.